Találati lista | Tudóstér

001-es BibID:	BIBFORM113310
035-os BibID:	(cikkazonosító)106679 (Scopus)85150079527 (WOS)000953520500001
Első szerző:	Rizzo, Manfredi
Cím:	Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD) : A position paper from the International Lipid Expert Panel (ILEP) / Rizzo Manfredi, Colletti Alessandro, Penson Peter E., Katsiki Niki, Mikhailidis Dimitri P., Toth Peter P., Gouni-Berthold Ioanna, Mancini John, Marais David, Moriarty Patrick, Ruscica Massimiliano, Sahebkar Amirhossein, Vinereanu Dragos, Cicero Arrigo Francesco Giuseppe, Banach Maciej, International Lipid Expert Panel (ILEP)
Dátum:	2023
ISSN:	1043-6618
Megjegyzések:	Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10?25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease. The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Adult Cardiovascular Diseases Child Diabetes Mellitus, Type 2 Dietary Supplements Humans Lipids Liver Cirrhosis Non-alcoholic Fatty Liver Disease
Megjelenés:	Pharmacological Research. - 189 (2023), p. 1-8. -
További szerzők:	Colletti, Alessandro Penson, Peter E. Katsiki, Niki Mikhailidis, Dimitri P. Tóth Péter P. Gouni-Berthold, Ioanna Mancini, John Marais, David Moriarty, Patrick M. Ruscica, Massimiliano Sahebkar, Amirhossein Vinereanu, Dragos Cicero, Arrigo F. G. Banach, Maciej Paragh György (1953-) (belgyógyász) International Lipid Expert Panel (ILEP)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: